1.Quality of hepatitis B vaccine derived from human plasma produced from 1997 to 1999 in Vietnam
Journal of Preventive Medicine 2001;11(2):63-66
28 lots of HB vaccine, produced from 1997 to 1999, have been tested for sterility, safety, potency and pyrogenicity. All of the 28 lots meet the WHO's requirements for human plasma-derived hepatitis B vaccine
Hepatitis B Vaccines
;
Vaccines
2.Assessment of immunity response capacity of B hepatitis vaccine in seaman in Hai Phong city
Journal of Practical Medicine 2004;490(10):54-59
110 seaman in Hai Phong were infected Engerise B vaccine Good immune response through antibody responsivity effect was reached. For the first injectiong, the responsivity in 72,73% of cases, GMT altained to 135,5 mIU/ml; for the 2nd and the 3 rd injections, the respective values were 81,82%, 94,55% and 327,2 mIU/ml, 680,5 mIU/ml, with p>0,05 and p< 0,001. Topic and systemic side effect rates were very low.
Hepatitis B Vaccines
;
Viral Hepatitis Vaccines
;
Male
3.Anti-HBs antibody efficacy in children after vaccination with the first generation of hepatitis B vaccine
Journal of Practical Medicine 2002;435(11):22-25
Antibody efficacy was investigated on 98 children after hepatitis B vaccination at time of 30 months after the first dose in HuÕ City. It was found that only 30.6% of children who were vaccinated in 1998 have antibody response at protectable level. 100% of those have low-level antibody response. Cause of poor antibody response can be the duration between the first and the third doses is short. 100% of children were injected vaccine at the delta muscle, instead of the lateral-anterior thigh.
Hepatitis B Vaccines
;
child
4.Anti-HBs formation in only anti-HBc positive persons after one injection of hepatitis B vaccine.
Joo Yeon KIM ; Ji Yeon JANG ; Hyun Rim CHOI
Journal of the Korean Academy of Family Medicine 1993;14(11):725-733
No abstract available.
Hepatitis B Vaccines*
;
Hepatitis B*
;
Hepatitis*
;
Humans
5.Hepatitis A vaccines.
The Medical journal of Malaysia 2005;60 Suppl C():112-5
Hepatitis A, an acute usually self limiting infection of the liver is one of the most common vaccine-preventable infectious disease in the world. Effective vaccines which provide long term immunity against hepatitis A have been available since 1992. They are of known good quality, well tolerated with no serious adverse events and have been successfully used to protect different populations from infection as well as interrupt outbreak in closed communities. Mathematical models estimate the long term persistence of antiHAV antibodies to be more than 25 years. Vaccination efforts should be supplemented by health education and improved sanitation. Planning for large scale immunization programmes against hepatitis A should take into consideration epidemiological and cost benefit studies.
Hepatitis A
;
seconds
;
Infection as complication of medical care
;
Hepatitis A Vaccines
;
Vaccines
6.Safety and immunogenicity of low-dose hepatitis B vaccine produced by National Institute of Hygiene and Epidemiology in newborns.
Journal of Preventive Medicine 2002;12(1):30-36
2 reduced doses of plasma-derived hepatitis B vaccine produced by the National Institute of Hygiene an Epidemiology (NIHE): 2.5g (VN2,5) and 5g (VN5) was compared with 2 pediatric standard doses (10g) of recombinant vaccine from 2 Korean companies. The vaccines were administrated intramuscularly in 700 neonates at months 0, 1, 2 with postvaccineation serology tested at month 8. The seroconversion rate of 2 reduced doses are comparable with 2 control groups. Geometric mean titer of low-risk newborns in group VN2,5 were similar to group VN5, but significantly lower than control groups.
Hepatitis B
;
Infant, Newborn
;
Hepatitis B Vaccines
7.Study on purification of hepatitis A virus strain HM-175 from primary monkey kidney cell culture of Maccaca mulatta for preparation of an inactivated hepatitis A vaccine
Journal of Preventive Medicine 1999;9(4):31-38
Monolayer primary monkey kidney cell culture was infected with vaccine production hepatitis A virus strain HM-175 at a multiplicity of infection (MOI) of 0.05 PFU cell and incubation period was 21 days. Then the culture was stored at 70oC. Freeze and thaw 3 times for cell breakage and virus release. Centrifugation for separation of cell debris, then cell debris was sonicated with 3 cycles of 30 second and 30 seconds intervals, centrifugation separation of cell debris. Cell culture supernatant and supernatant after centrifugation were mixed for further ultrafitration and concentration using filtration system pellicon following one rate-zonal ultracetrifugation in sucrose gradient solution were conducted for HAV separation and purification. A purified solution of HAV antigen including empty and full particles was obtained by using this method, which was further, treated with 1/2000 formalin for HAV inactivation at 35oC - 96h. Hepatitis A vaccine prepared by this method meets the WHO minimum requirement for this vaccine.
Hepatitis A virus
;
kidney
;
cells
;
Hepatitis A Vaccines
8.Study on adaptation of hepatitis A virus strain HM-175 to primary monkey kidney cell culture for preparation of an inactivated hepatitis A vaccine
Journal of Preventive Medicine 1999;9(4):24-31
The hepatitis A virus strain HM-175 was adapted to primary monkey kidney cell culture Maccaca mulatta for the study of development of an inactivated purified hepatitis A vaccine derived from cell culture. Using immuno-fluorescent method, it was detected that the hepatitis A viruses replicated very well inside cytoplasma and induced a typical cytophatic effect. After 10 days of inoculation, about 50% of cells were infected. Hepatitis A viruses replicated very slowly. This study found that the time for complet inducing CPE was 21 days and titers of released viruses and cell associated viruses are similar. Therefore, the procedure for preparation of hepatitis A vaccine should include the step of cell sonication for separation of all cells associated viruses. 10 days after inoculation was the best time to have high titer. A serial passage of HAV HM-175 on primary cell culture of monkey kidney was not successful in getting higher titer and shorter time of inoculation, so it was not necessary to conduct serial passages. The optimal infectious dose was determinated as 0.03 pfu/cell
Hepatitis A virus
;
kidney
;
cells
;
Hepatitis A Vaccines
9.Study on adaptation of hepatitis A virus strain HM-175 to primary monkey kidney cell culture for preparation of an inactivated hepatitis A vaccine
Journal of Preventive Medicine 2002;12(2):24-31
The hepatitis A virus strain HM-175 was adapted to primary monkey kidney cell culture Maccaca mulatta for the study of development of an inactivated purified hepatitis A vaccine derived from cell culture. Using immuno-fluorescent method, it was detected that the hepatitis A viruses replicated very well inside cytoplasma and induced a typical cytophatic effect. After 10 days of inoculation, about 50% of cells were infected. Hepatitis A viruses replicated very slowly. This study found that the time for complet inducing CPE was 21 days and titers of released viruses and cell associated viruses are similar. Therefore, the procedure for preparation of hepatitis A vaccine should include the step of cell sonication for separation of all cells associated viruses. 10 days after inoculation was the best time to have high titer. A serial passage of HAV HM-175 on primary cell culture of monkey kidney was not successful in getting higher titer and shorter time of inoculation, so it was not necessary to conduct serial passages. The optimal infectious dose was determinated as 0.03 pfu/cell
Hepatitis A virus
;
kidney
;
cells
;
Hepatitis A Vaccines
10.Immunological response of children under one year old in Nha Trang after vaccination with hepatitis B vaccine produced by NIHE, Ha Noi
Journal of Preventive Medicine 1999;9(1):26-30
A study on immunogenicity of hepatitis B vaccine produced by NIHE, Hanoi was conducted on 240 children under 1 year old in Nha Trang during 1994-1996. The vaccination schedule was 0, 1, 6 month. Blood sampling was performed at 3, 7, 12 month after vaccination. All children were given 10g/dose. The immunogenicity was following: seroconvertion rates were 82.89%, 96.97% and 97.97% with GMT: 120.69, 473.38 and 258.2 UI/L, respectively. The antibody response rates were the same in 2 groups, but GMT of newborn was higher than on children of 6-12 months old and there was a statistical significant difference.
Immunization
;
hepatitis B vaccines
;
child